2011
DOI: 10.1021/jm2002074
|View full text |Cite
|
Sign up to set email alerts
|

Organometallic Ruthenium(II) Arene Compounds with Antiangiogenic Activity

Abstract: The antimetastatic ruthenium(II) compounds [Ru(η(6)-p-cymene)Cl(2)(PTA)] (PTA = 1,3,5-triaza-7-phosphaadamantane) (RAPTA-C) and [Ru(η(6)-toluene)Cl(2)(PTA)] (RAPTA-T), as well as their analogues [Ru(η(6)-p-cymene)Cl(2)(DAPTA)] (DAPTA = (3,7-diacetyl-1,3,7-triaza-5-phosphabicyclo[3.3.1]nonane)) (DAPTA-C) and [Ru(η(6)-toluene)Cl(2)(DAPTA)] (DAPTA-T), respectively, were tested in in vitro bioassays for endothelial cell function. All compounds showed low toxicity profiles and similar dose-dependent antiproliferati… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

4
205
0
5

Year Published

2011
2011
2020
2020

Publication Types

Select...
7
3

Relationship

2
8

Authors

Journals

citations
Cited by 239 publications
(214 citation statements)
references
References 39 publications
4
205
0
5
Order By: Relevance
“…We have previously shown a similar phenomenon for ruthenium-arene-based compounds possessing anti-angiogenic properties [27]. We hypothesize that this shows that developmental angiogenesis is a more robust process that is probably more intricately regulated, and more well-balanced, than the process that follows the sudden PDT challenge.…”
Section: Discussionsupporting
confidence: 58%
“…We have previously shown a similar phenomenon for ruthenium-arene-based compounds possessing anti-angiogenic properties [27]. We hypothesize that this shows that developmental angiogenesis is a more robust process that is probably more intricately regulated, and more well-balanced, than the process that follows the sudden PDT challenge.…”
Section: Discussionsupporting
confidence: 58%
“…the Lewis lung carcinoma, and is currently undergoing phase II clinical trials [13]. Similarly, the ruthenium(II) organometallic complex [Ru(η6-toluene)Cl2(PTA)] (where PTA=1,3,5-triaza-7-phosphatricyclo-[3.3.1.1] decane) named RAPTA-T is weakly cytotoxic in vitro, while showing favorable antimetastatic effects in vivo [14], as well as remarkable anti-angiogenic properties [15]. The mode of action of antimetastatic ruthenium compounds remains elusive and largely unexplored.…”
Section: Introductionmentioning
confidence: 99%
“…6,7 Third, the risk of neurological injury after treatment of unruptured BAVM may be greater than previously described. [8][9][10] A randomized trial of unruptured brain arteriovenous malformations (ARUBA) was designed to compare the risk of observation versus prophylactic intervention for patients diagnosed with unruptured BAVM. The primary end points of the ARUBA trial are the composite risk of death or stroke and risk of death or clinical impairment, defined as a modified Rankin Score (MRS) ≥2.…”
mentioning
confidence: 99%